Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports.

Is AnaptysBio, Inc. (ANAB) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday. Shares of Progress Software Corporation PRGS fell sharply in today's pre-market trading ...

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

The Biotech Beach Hotbed includes San Diego, Los Angeles and the surrounding (Torrey Pines, Thousand Oaks) regions of Southern California. SoCal is well-known for its sprawling beaches and ...

Building on this legacy of innovation, LG did the unthinkable yet again with the announcement of the first-ever transparent OLED TV in the world in 2024. LG's see-through 77" TV with 4K UHD ...

In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company’s shares closed last Friday at $15.85.